Merck & Co., Inc. (MRK) Intrinsic Value & DCF Valuation
Drug Manufacturers - General · NYSE
Current Price
$130.39
Intrinsic Value
$118.2
-10.3% margin of safety
What Is Merck & Co., Inc.'s Intrinsic Value?
As of 2026-07-29, the base-case DCF model estimates the intrinsic value of Merck & Co., Inc. (MRK) at $118.2 per share, compared with a market price of $130.39, a margin of safety of -10.3%. The base case assumes 3.0% annual free cash flow growth and a 10.0% discount rate.
Across the sensitivity grid the estimate spans $96.89 to $142.68. Intrinsic value is an estimate built on assumptions, not a fact. A higher discount rate or slower growth pushes the estimate down, while stronger cash flow growth lifts it.
How the DCF works · Recalculate with your own assumptions · What is intrinsic value?
Is Merck & Co., Inc. (MRK) Undervalued?
At $130.39, MRK trades about 10.3% above the base-case intrinsic value estimate, a modest premium. By this model the price sits within a normal band, though faster growth than assumed would change the picture.
COMPETITIVE MOAT
↑Blockbuster drug Keytruda dominance
Keytruda is a leading oncology drug with broad indications and strong clinical data. Its established market position and ongoing research create significant barriers to entry.
↑Strong R&D pipeline and innovation
Merck consistently invests heavily in research and development, leading to a robust pipeline of new drugs. This innovation fuels future growth and competitive advantage.
↑Global manufacturing and distribution scale
Merck's extensive global infrastructure allows for efficient production and widespread access to its medicines. This scale is difficult for smaller competitors to replicate.
INVESTMENT RISKS
↓Regulatory and political headwinds
Increased scrutiny from lawmakers and potential policy changes regarding drug pricing could impact profitability. Investigations into clinical trials add further uncertainty.
↓Pipeline failures and R&D setbacks
Despite a strong pipeline, drug development is inherently risky. A significant failure in late-stage trials could negatively impact future revenue streams.
↓Intensifying competition in oncology
The oncology market is highly competitive, with numerous companies developing novel treatments. Merck faces constant pressure to maintain its leadership position.
Base case
MRK base case valuation
Intrinsic Value
$118.2
Margin of safety
-10.3%
Expected annual return
-1.9%
Base case assumptions: 3.0% annual growth, 10.0% discount rate, 23x exit multiple, 5 year projection. Data as of 2026-07-29.
This base case uses default assumptions and is not financial advice. The intrinsic value changes significantly when the growth rate or discount rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.
Customize the MRK valuation
Adjust the growth rate, discount rate, and exit multiple to see how the intrinsic value and margin of safety for Merck & Co., Inc. respond.
Open DCF Calculator for MRKCompany Overview
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Financial Metrics — MRK Stock Valuation Data
Revenue/Share (TTM)
$26.53
FCF/Share (TTM)
$5.71
ROIC (TTM)
13.3%
ROE (TTM)
17.9%
P/FCF
22.8x
EV/EBITDA
19.5x
FCF Yield
4.38%
Debt/Equity
1.07x
Based on trailing twelve-month data, MRK shows a free cash flow per share of $5.71 and a ROIC of 13.3%, key inputs for stock valuation using the DCF method. The P/FCF ratio of 22.8x and FCF yield of 4.38% are important context metrics when evaluating MRK's stock valuation relative to peers.
Frequently Asked Questions
What is the intrinsic value of MRK?
Merck & Co., Inc. currently generates $5.71 in free cash flow per share. At the current price of $130.39, a DCF model would discount these cash flows at an appropriate WACC and apply a terminal growth rate to arrive at an intrinsic value. The result depends heavily on your growth and discount rate assumptions — a 1% change in WACC typically shifts the fair value estimate by 10-15%. In MiniValuator the model uses a single discount rate that you can edit directly, 10% by default, rather than a computed WACC.
Is MRK undervalued?
MRK trades at a P/FCF ratio of 22.8x with a free cash flow yield of 4.38%. This P/FCF is in a moderate range. However, whether MRK is truly undervalued requires comparing the DCF intrinsic value to the current market price and evaluating whether the margin of safety is sufficient for your risk tolerance.
How do I value MRK stock using DCF?
To perform a DCF valuation on Merck & Co., Inc.: (1) Start with the trailing free cash flow per share ($5.71) as the base, (2) project future FCF growth over 5-10 years based on Drug Manufacturers - General industry trends and company fundamentals, (3) apply a discount rate (WACC) reflecting MRK's risk profile — with a debt-to-equity of 1.07x, capital structure is an important factor, and (4) add a terminal value for cash flows beyond the projection period.
What is DCF valuation and how does it apply to MRK?
DCF (Discounted Cash Flow) estimates what a company is worth today based on its future cash generation. For Merck & Co., Inc., this means projecting how much free cash flow the company will produce over the next 5-10 years, shaped by Drug Manufacturers - General trends, then discounting those amounts to today's dollars. MRK's ROIC of 13.3% shows moderate capital returns.
How does WACC affect MRK stock valuation?
WACC (Weighted Average Cost of Capital) is the discount rate in a DCF model — it reflects the minimum return investors require. For MRK, with a debt-to-equity ratio of 1.07x, the capital structure directly influences WACC. A 1% increase in WACC typically reduces the intrinsic value by 10-15%. At an EV/EBITDA of 19.5x, the market's implied discount rate can be reverse-engineered for comparison. In MiniValuator you set this discount rate yourself as a single editable number, 10% by default, instead of computing a formal WACC.
Learn More
- See MRK PE Valuation → — Earnings-based stock valuation using PE ratio analysis
- DCF Methodology — Step-by-step guide to discounted cash flow analysis
- PE Methodology — Guide to PE ratio stock valuation
- WACC — Understanding the discount rate used in DCF
- Margin of Safety — How to evaluate downside protection
- Intrinsic Value — How to evaluate stock fair value
- How to Calculate Intrinsic Value — Complete guide for investors
Related Valuations
All Healthcare valuationsDCF and P/E value MRK with different methods and assumptions, so the two conclusions can differ. Compare the P/E fair value.
Price as of 2026-07-29. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.